June Virtual Equity Conference - Ocugen (OCGN)
... orphan designations or millions of patients presenting for the company today is dr shankar musenuri the ceo welcome dr menuri ...
Chief Executive Officer, Ocugen
Search every verified Shankar Musunuri interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a January 2023 podcast appearance, Shankar Musunuri, Chairman, CEO, and co-founder of Ocugen, discussed the company's efforts to develop an improved COVID-19 vaccine. He stated that the current vaccine landscape warrants a new approach, citing statistics on COVID-19 deaths in 2021 surpassing those in 2020 despite vaccination efforts. Musunuri argued that a better vaccine should require fewer shots, offer more durable protection, and reduce transmission among vaccinated individuals, noting that controlling transmission is a critical public health priority, particularly for the elderly and immunocompromised. Musunuri also detailed Ocugen's broader pipeline, mentioning plans to file two Investigational New Drug applications in the second quarter of the following year for gene therapies targeting rare diseases and a larger orphan disease population. He emphasized the company's commitment to ensuring global patient access to its therapies, stating that Ocugen's work extends beyond market launch to providing access across the globe.
... orphan designations or millions of patients presenting for the company today is dr shankar musenuri the ceo welcome dr menuri ...
Ocugen Co-Founder & CEO Shankar Musunuri, PhD.
Guest: Dr. Shankar Musunuri - Ocugen, Chairman, Chief Executive Officer, and Co-founder Website: www.ocugen.com Ticker: OCGN Bio: Dr. Shankar Musunuri is Chairman, CEO and Co-Founder of Ocugen. The company (NASDAQ: OCGN) is a publicly traded biotechnology company focused on discovery, development, commercialization of gene therapies, cell therapies, biologicals, and vaccines, based in Malvern, Pennsylvania. Dr. Musunuri transformed Ocugen from a start-up into a cutting-edge science-based biotech powerhouse with three distinct first-in-class platform technologies focused on ophthalmology wi…
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases…
Join us on the latest episode! Our Guest: Dr. Shankar Musunuri, Chairman, CEO and Co-Founder Ocugen What you'll get out of this episode: Dr. Shankar Musunuri of Ocugen discusses gene and cell therapy innovations Focus on tackling unmet needs in ophthalmology and vaccine development Insights into Ocugen's unique platforms and global health impact Future prospects in biotech and healthcare advancements To learn more about Ocugen: Website: https://www.ocugen.com/ LinkedIn: / ocugen Our sponsor for this episode are: Sage Growth Partners https://sage-growth.com/ #Biotech #HealthcareInnovati…
Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder & CEO Shankar Musunuri, Ph.D. says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology. How would such a vaccine be produced? Dr. Musunuri lays out the manufacturing science— and why the improved COVID vaccine his company is currently putting through Phase 2/3 trials makes good business sense—on this week's episode of the Business of Biotech. #businessofbiotech #biopharma #biotech #cy…
Shankar Musunuri, Ph.D., Co-founder, Chairman and CEO Malvern, PA (NASDAQ: OCGN)
Returning guest, Dr. Shankar Musunuri, Chairman, Co-founder, and CEO of Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines discusses the company's current work on a vaccine to treat COVID-19. They have recently acquired the rights to develop and commercialize an intranasal COVID-19 vaccine from Washington University for the U.S., Europe, and Japan markets. In addition to infectious diseases, they also have a robust pipeline to treat eye disease and orthopedics. #Ocugen Shankar Musunuri, PhD., MBA: Dr.…
12 months ago Covid vaccines remained a distant prospect. But whilst the scientific achievement of developing effective jabs so quickly should not be at all underestimated – the race now to vaccinate has come to the forefront and remains uneven and incomplete. We find out what were the challenges in this epic race against the virus and ask what remain the hurdles and opportunities for the global pharmaceutical industry.
Kristen Kluska of Cantor Fitzgerald hosted a virtual fireside chat featuring CEO Dr. Shankar Musunuri and members of the Vaccine Scientific Advisory Board to discuss #COVAXIN #COVID-19 #vaccine development in the US
Eye-health company Ocugen shares surge more than 425 percent year-to-date after the company got involved in distributing Covid-19 vaccines. Shankar Musunuri, Ocugen CEO, joins 'Closing Bell' to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the lead…
Ocugen CEO Shankar Musunuri’s presentation from NobleCon17, January 2021. Following a formal presentation, Shankar is joined by Noble Capital Markets Senior Research Analyst Ahu Demir, PhD for a Q&A session, featuring questions submitted by the NobleCon live audience. More information on Ocugen, including recent news and advanced market data is available (at no cost) at https://www.channelchek.com/company/OCGN Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underse…
Sign in to search the full transcript archive, filter by topic, and access every quote from Shankar Musunuri.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans